Clobetasol



Combined with:

Indications and Reactions:

Role Indications Reactions
Primary
Psoriasis 40.0%
Diabetes Mellitus 10.0%
Pemphigoid 10.0%
Toxic Skin Eruption 10.0%
Dermatitis 5.0%
Essential Hypertension 5.0%
Hyperlipidaemia 5.0%
Paraneoplastic Pemphigus 5.0%
Product Used For Unknown Indication 5.0%
Prophylaxis 5.0%
Dizziness 10.0%
Drug Ineffective 10.0%
Dyspnoea 10.0%
Osteopenia 10.0%
Perivascular Dermatitis 10.0%
Plagiocephaly 10.0%
Pre-existing Disease 10.0%
Skin Atrophy 10.0%
Tremor 10.0%
Whipple's Disease 10.0%
Secondary
Product Used For Unknown Indication 20.5%
Psoriasis 15.4%
Foetal Exposure During Pregnancy 9.4%
Asthma 7.7%
Respiratory Tract Infection 7.7%
Type 2 Diabetes Mellitus 3.4%
Antiallergic Therapy 2.6%
Atrophic Vulvovaginitis 2.6%
Chronic Hepatitis C 2.6%
Depression 2.6%
Essential Hypertension 2.6%
Fibromyalgia 2.6%
Headache 2.6%
Hypothyroidism 2.6%
Immunosuppression 2.6%
Migraine 2.6%
Myocardial Ischaemia 2.6%
Nausea 2.6%
Oral Disorder 2.6%
Steroid Therapy 2.6%
Alopecia 12.0%
Otitis Media Chronic 8.0%
Pain 8.0%
Stress 8.0%
Diabetes Mellitus 4.0%
Dizziness 4.0%
Drug Ineffective 4.0%
Drug Ineffective For Unapproved Indication 4.0%
Hypertension 4.0%
Lacrimation Increased 4.0%
Off Label Use 4.0%
Oropharyngeal Pain 4.0%
Psoriatic Arthropathy 4.0%
Pulmonary Embolism 4.0%
Rash 4.0%
Rash Generalised 4.0%
Rash Pruritic 4.0%
Skin Disorder 4.0%
Thrombosis 4.0%
Tinea Capitis 4.0%
Concomitant
Product Used For Unknown Indication 41.9%
Psoriasis 25.7%
Psoriatic Arthropathy 4.2%
Hypertension 3.5%
Pain 3.3%
Asthma 2.4%
Depression 2.0%
Gastrooesophageal Reflux Disease 1.9%
Anxiety 1.7%
Rheumatoid Arthritis 1.6%
Diabetes Mellitus 1.5%
Crohn's Disease 1.5%
Hypersensitivity 1.4%
Drug Use For Unknown Indication 1.3%
Blood Pressure 1.2%
Blood Cholesterol Increased 1.1%
Vitamin Supplementation 1.1%
Back Pain 1.0%
Insomnia 0.9%
Multiple Sclerosis 0.9%
Psoriasis 22.5%
Injection Site Pain 10.8%
Drug Ineffective 10.3%
Pain 4.2%
Pulmonary Embolism 4.2%
Rash 4.2%
Injection Site Erythema 3.8%
Injection Site Haemorrhage 3.8%
Headache 3.3%
Injection Site Swelling 3.3%
Pain In Extremity 3.3%
Sinusitis 3.3%
Urticaria 3.3%
Vomiting 3.3%
Weight Increased 3.3%
Therapeutic Response Decreased 2.8%
Thrombocytopenia 2.8%
Wrong Technique In Drug Usage Process 2.8%
Injection Site Reaction 2.3%
Nausea 2.3%
Interacting
Rash 66.7%
Chronic Hepatitis C 33.3%
Drug Interaction 50.0%
Malaise 50.0%